Cost Is the Biggest Barrier to Ongentys Adherence

You've made the clinical decision that your Parkinson's patient needs Ongentys (Opicapone) to manage off episodes. The once-daily dosing is convenient, the safety profile is favorable, and the clinical data supports it. But then your patient calls back: they can't afford it.

At $645 to $1,003 per month without insurance, Ongentys is a significant financial burden — and even with insurance, Tier 4 copays can run $50 to $150+ per fill. For patients on fixed incomes, especially those on Medicare with coverage gaps, the cost can be the difference between adherence and abandonment.

This guide gives you practical, actionable strategies to help your patients access Ongentys affordably — or find appropriate alternatives when cost remains prohibitive.

What Patients Are Actually Paying

Understanding the financial landscape helps you anticipate barriers before they derail treatment:

• Cash price (uninsured): $645–$1,003/month for 30 capsules of 50 mg
• Commercial insurance: Typically Tier 4 (specialty/non-preferred brand). Copays range from $50–$150+, depending on plan design.
• Medicare Part D: Covered by most plans at Tier 4. Patients hit the coverage gap ("donut hole") faster with high-cost specialty drugs, and catastrophic coverage still requires 5% coinsurance — which on a $1,000 drug is not trivial.
• Prior authorization: Required by most payers. Some require step therapy with Entacapone first.

The key takeaway: even insured patients may face substantial out-of-pocket costs, and the prior authorization process itself can delay treatment initiation by days to weeks.

Manufacturer Savings Programs

Ongentys Savings Program (Copay Card)

Neurocrine Biosciences offers a copay savings program for eligible commercially insured patients:

• Eligible patients may pay as little as $25 per prescription
• Applied automatically at participating pharmacies
• Not valid for patients with government insurance (Medicare, Medicaid, Tricare, VA)
• No income requirements for commercially insured patients

This is the first tool to deploy for any commercially insured patient. Ensure your staff mentions it at the point of prescribing, and consider having enrollment information available in your office.

INBRACE Support Program

Neurocrine's INBRACE Support Program provides comprehensive access support:

• Insurance navigation — Helps patients understand their coverage and out-of-pocket costs
• Prior authorization assistance — Partners with CoverMyMeds to streamline the PA process
• Field-based Reimbursement and Patient Access Managers (RPAMs) — Dedicated representatives who can work directly with your practice and patients
• Pharmacy coordination — Helps identify pharmacies that stock Ongentys

For providers, the INBRACE program is particularly valuable for the prior authorization support. If your practice handles high volumes of specialty PAs, connecting with your local RPAM can save significant administrative time.

Coupon and Discount Cards

For patients paying cash or with high-deductible plans, third-party discount programs can sometimes reduce costs:

• GoodRx — Shows prices at nearby pharmacies with available coupons
• SingleCare — Free prescription savings cards accepted at most pharmacies
• RxSaver — Compares prices across pharmacy chains

However, be transparent with patients: discount cards typically offer modest savings on brand-name specialty drugs like Ongentys. The manufacturer copay card will almost always provide better value for commercially insured patients. Discount cards are most useful for uninsured patients who don't qualify for patient assistance programs.

Patients can also check our comprehensive guide to saving money on Ongentys for a full rundown of options.

Patient Assistance Programs

For uninsured or underinsured patients who cannot afford Ongentys at any available price:

• NeedyMeds (needymeds.org) — Database of patient assistance programs, including manufacturer programs and independent foundations
• RxAssist (rxassist.org) — Comprehensive database of assistance programs searchable by medication
• RxHope (rxhope.com) — Connects patients to manufacturer-sponsored assistance programs

Eligibility typically requires documented financial hardship, and the application process can take 2-4 weeks. Plan accordingly — if you anticipate a patient will need assistance, start the process early, ideally while they're still on their current regimen.

Generic Alternatives and Therapeutic Substitution

When cost remains prohibitive despite all available programs, consider these clinically appropriate alternatives:

Entacapone (Comtan) — Generic Available

The most direct therapeutic alternative. Key considerations:

• Cost: ~$40–$50/month with a coupon (generic)
• Dosing: 200 mg with each dose of Levodopa (up to 8 times daily)
• Efficacy: Same drug class (COMT inhibitor), but requires multiple daily doses and may provide slightly less COMT inhibition
• Best for: Patients who are well-organized with medication schedules and for whom cost is the primary barrier

Stalevo (Levodopa/Carbidopa/Entacapone)

A combination tablet that bundles Levodopa, Carbidopa, and Entacapone into one pill. Simplifies the regimen for patients already taking all three. Generic versions are available at lower cost than brand Stalevo.

Tolcapone (Tasmar)

A potent COMT inhibitor reserved as second-line due to hepatotoxicity risk. Requires regular liver function monitoring. Only consider when other COMT inhibitors have failed and the patient cannot access Ongentys.

Istradefylline (Nourianz)

An adenosine A2A receptor antagonist — different mechanism entirely. May be an option when COMT inhibitors aren't effective or tolerated. Cost is also significant (~$700+/month), so the same access challenges may apply.

For a patient-facing comparison, see alternatives to Ongentys.

Building Cost Conversations into Your Workflow

The most effective cost intervention happens before the patient leaves your office. Here's how to integrate it:

1. Screen for Cost Barriers at the Point of Prescribing

Ask directly: "Do you have concerns about medication costs?" or "What does your insurance typically cover for brand-name medications?" Many patients won't volunteer this information, especially older adults who may see cost complaints as inappropriate.

2. Train Your Staff on Available Programs

Your medical assistants, nurses, and front desk staff should know about:

• The Ongentys copay card (for commercial insurance)
• The INBRACE Support Program phone number and enrollment process
• The prior authorization timeline and what patients should expect

3. Use a Benefits Investigation Before Prescribing

The INBRACE program offers benefits investigations that can tell you the patient's expected copay before you write the prescription. This avoids the scenario where a patient gets to the pharmacy and discovers they can't afford it.

4. Document Step Therapy Failures

If your patient has tried and failed Entacapone (which many payers require before approving Ongentys), document it clearly in the chart. Specific documentation of why Entacapone was inadequate — poor off-time reduction, adherence issues with multiple daily doses, intolerable side effects — strengthens PA approvals.

5. Consider Mail-Order and Specialty Pharmacy Options

Some insurance plans offer lower copays through preferred mail-order or specialty pharmacies. Patients may not know about these options. The INBRACE program can help identify the most cost-effective pharmacy channel.

6. Provide Patient Resources

Direct patients to Medfinder for Providers — a tool designed to help healthcare professionals and patients find medications in stock and navigate access challenges. You can also share our patient-facing savings guide for Ongentys.

Final Thoughts

Ongentys is a valuable addition to the Parkinson's treatment arsenal, but its cost creates real barriers to patient access and adherence. As prescribers, we have more tools than ever to help patients afford their medications — from manufacturer copay cards and support programs to strategic therapeutic substitution when necessary.

The key is proactive intervention. Don't wait for the pharmacy call-back or the missed refill. Build cost conversations into your prescribing workflow, connect with your local Neurocrine RPAM, and keep Medfinder in your toolkit for when patients need help finding their medication in stock. When cost is addressed upfront, adherence follows.